Print E-mail
Volume 49, Number 1, February 2016

Intravenous immunoglobulin, pharmacogenomics, and Kawasaki disease 


Ho-Chang Kuo, Yu-Wen Hsu, Mei-Shin Wu, Shu-Chen Chien, Shih-Feng Liu, Wei-Chiao Chang


 

Corresponding author:

Wei-Chiao Chang,
Corresponding author. Department of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, No. 250, Wuxing St., Xinyi Dist., Taipei 11031, Taiwan. 



 

Background and purpose: 

Kawasaki disease (KD) is a systemic vasculitis of unknown etiology and it is therefore worth examining the multifactorial interaction of genes and environmental factors. Targeted genetic association and genome-wide association studies have helped to provide a better understanding of KD from infection to the immune-related response. Findings in the past decade have contributed to a major breakthrough in the genetics of KD, with the identification of several genomic regions linked to the pathogenesis of KD, including ITPKC, CD40, BLK, and FCGR2A. This review focuses on the factors associated with the genetic polymorphisms of KD and the pharmacogenomics of the response to treatment in patients with intravenous immunoglobulin resistance. 



 

Key words:

genetic polymorphisms, genome-wide association studies, intravenous immunoglobulin resistance, Kawasaki disease, pharmacogenomics